This suggested that the relationship between the MAPK signaling pathway and ZEB2 was likely not direct and could be influenced by multiple, complex factors, indicating that the MAPK signaling pathway may not be a primary regulator of ZEB2 expression in EGFR-TKI-resistant NSCLC cells. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.